Profile data is unavailable for this security.
About the company
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.
- Revenue in HKD (TTM)1.53bn
- Net income in HKD-1.75bn
- Incorporated2008
- Employees3.50k
- LocationRemeGen Co LtdNo.1 Rongchang Road, Yantai ETDZYANTAI 264006ChinaCHN
- Phone+86 5 353573685
- Fax+86 5 356113517
- Websitehttp://www.remegen.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alphamab Oncology | 281.16m | -236.94m | 2.37bn | 429.00 | -- | 1.33 | -- | 8.43 | -0.2461 | -0.2461 | 0.292 | 1.85 | 0.1145 | 0.8256 | 13.94 | 646,355.90 | -9.65 | -18.72 | -11.16 | -21.94 | 79.33 | -- | -84.27 | -415.55 | 4.42 | -- | 0.167 | -- | 31.12 | -- | 35.35 | -- | -13.12 | -- |
Biocytogen Pharmaceuticals Beijng Co Ltd | 879.72m | -267.92m | 2.66bn | 1.04k | -- | 3.27 | -- | 3.02 | -0.6727 | -0.6727 | 2.21 | 2.04 | 0.3109 | 23.64 | 5.35 | 825,251.70 | -9.47 | -- | -12.44 | -- | 71.97 | -- | -30.46 | -- | 1.33 | -3.22 | 0.436 | -- | 34.28 | -- | 36.38 | -- | -- | -- |
Lepu Biopharma Co Ltd | 225.36m | -79.80m | 4.88bn | 491.00 | -- | 4.85 | 410.69 | 21.64 | -0.0473 | -0.0473 | 0.1354 | 0.5876 | 0.0847 | 1.86 | 1.53 | 525,305.40 | -3.53 | -- | -5.72 | -- | 78.76 | -- | -41.62 | -- | 0.7322 | -2.63 | 0.4621 | -- | 1,347.16 | -- | 96.79 | -- | -- | -- |
Qyuns Therapeutics Co Ltd | 49.36m | -463.50m | 5.97bn | 325.00 | -- | 13.64 | -- | 121.05 | -1.98 | -1.98 | 0.224 | 1.97 | -- | -- | -- | 149,122.70 | -- | -- | -- | -- | 84.05 | -- | -976.77 | -- | 1.83 | -28.07 | 0.5795 | -- | -- | -- | -70.28 | -- | -- | -- |
Keymed Biosciences Inc | 89.73m | -816.53m | 11.12bn | 1.12k | -- | 3.84 | -- | 123.95 | -3.12 | -3.12 | 0.3432 | 10.36 | 0.0207 | 0.3115 | 7.74 | 100,027.90 | -18.86 | -- | -20.96 | -- | 68.65 | -- | -909.38 | -- | 4.83 | -- | 0.2155 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
Ascentage Pharma Group International | 992.30m | -395.90m | 11.29bn | 574.00 | -- | 13.39 | -- | 11.38 | -1.37 | -1.37 | 3.41 | 2.68 | 0.2998 | 3.49 | 2.19 | 1,702,060.00 | -11.97 | -44.93 | -16.78 | -57.04 | 96.96 | 87.68 | -39.93 | -976.10 | 1.83 | -6.44 | 0.6865 | -- | 5.85 | 100.76 | -4.84 | -- | 2.82 | -- |
TYK Medicines Inc | 0.00 | -470.25m | 11.65bn | 144.00 | -- | -- | -- | -- | -1.27 | -1.27 | 0.00 | -3.10 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -68.75 | -- | -- | -100.00 | -- | -22.97 | -- | -- | -- |
RemeGen Co Ltd | 1.53bn | -1.75bn | 11.67bn | 3.50k | -- | 2.15 | -- | 7.60 | -3.24 | -3.24 | 2.85 | 5.43 | 0.2411 | 0.4413 | 4.03 | 424,561.30 | -27.42 | -18.66 | -35.04 | -23.75 | 77.11 | 81.94 | -113.72 | -102.88 | 1.06 | -31.34 | 0.4737 | -- | 40.16 | 148.65 | -51.30 | -- | 59.07 | -- |
InnoCare Pharma Ltd | 857.91m | -517.44m | 12.13bn | 1.09k | -- | 1.35 | -- | 14.13 | -0.3064 | -0.3064 | 0.5079 | 4.31 | 0.0786 | 0.9875 | 3.19 | 787,793.40 | -4.88 | -13.41 | -6.20 | -15.36 | 85.59 | 85.99 | -62.04 | -172.16 | 3.77 | -- | 0.1667 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
Genscript Biotech Corp | 7.87bn | -1.38bn | 25.84bn | 7.28k | -- | 2.73 | -- | 3.28 | -0.6518 | -0.6518 | 3.72 | 4.45 | 0.3006 | 9.15 | 7.99 | 1,134,343.00 | -9.68 | -18.34 | -14.76 | -26.15 | 53.63 | 54.68 | -32.19 | -64.91 | 4.06 | -- | 0.1972 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
Data as of Sep 20 2024. Currency figures normalised to RemeGen Co Ltd's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
E Fund Management Co., Ltd.as of 18 Jun 2024 | 9.16m | 4.83% |
Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 7.24m | 3.82% |
The Vanguard Group, Inc.as of 04 Sep 2024 | 5.72m | 3.02% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 5.00m | 2.64% |
Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 5.00m | 2.64% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 4.27m | 2.25% |
First Seafront Fund Management Co., Ltd.as of 31 Dec 2023 | 3.34m | 1.76% |
Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 2.82m | 1.49% |
Schroder Investment Management (Hong Kong) Ltd.as of 31 May 2024 | 2.52m | 1.33% |
CITIC Securities Co., Ltd. (Invt Port)as of 31 Dec 2023 | 2.24m | 1.18% |
More ▼
Data from 31 Dec 2023 - 12 Sep 2024Source: FactSet Research Systems Inc.